{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T06:33:22Z","timestamp":1792996402673,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd014707","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000}}],"reference-count":215,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd014707.pub2","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:00:54Z","timestamp":1789470054000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacological therapies for the prevention of fractures in men"],"prefix":"10.1002","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2560-2556","authenticated-orcid":false,"given":"Lars Christian","family":"Braten","sequence":"additional","affiliation":[{"name":"School of Public Health and Preventive Medicine; Monash University; Melbourne Australia"},{"name":"Research and Communication Unit for Musculoskeletal Health (FORMI); Oslo University Hospital; Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8383-7479","authenticated-orcid":false,"given":"Cyrill","family":"Suter","sequence":"additional","affiliation":[{"name":"Finnish Centre for Evidence-Based Orthopaedics (FICEBO), Department of Orthopaedics and Traumatology; University of Helsinki and Helsinki University Hospital; Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3901-1164","authenticated-orcid":false,"given":"Renea V","family":"Johnston","sequence":"additional","affiliation":[{"name":"School of Public Health and Preventive Medicine; Monash University; Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3151-025X","authenticated-orcid":false,"given":"Sami A","family":"Hartzell","sequence":"additional","affiliation":[{"name":"Finnish Centre for Evidence-Based Orthopaedics (FICEBO), Department of Orthopaedics and Traumatology; University of Helsinki and Helsinki University Hospital; Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3713-956X","authenticated-orcid":false,"given":"Teppo","family":"J\u00e4rvinen","sequence":"additional","affiliation":[{"name":"Finnish Centre for Evidence-Based Orthopaedics (FICEBO), Department of Orthopaedics and Traumatology; University of Helsinki and Helsinki University Hospital; Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0597-0933","authenticated-orcid":false,"given":"Rachelle","family":"Buchbinder","sequence":"additional","affiliation":[{"name":"School of Public Health and Preventive Medicine; Monash University; Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"10.1002\/14651858.CD014707.pub2-BIB0001|cit1","unstructured":"World Health Organization WHO scientific group on the assessment of osteoporosis at the primary health care level https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/42841\/WHO_TRS_921.pdf?sequence=1&isAllowed=y"},{"issue":"8","key":"10.1002\/14651858.CD014707.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1210\/jc.2018-02614","article-title":"Two-thirds of all fractures are not attributable to osteoporosis and advancing age: implications for fracture prevention","volume":"104","author":"Mai","year":"2019","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"11","key":"10.1002\/14651858.CD014707.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00198-006-0160-8","article-title":"Bone fragility in men \u2013 where are we?","volume":"17","author":"Seeman","year":"2006","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.bone.2018.06.004","article-title":"Fracture incidence and secular trends between 1989 and 2013 in a population based cohort: the Rotterdam Study","volume":"114","author":"Trajanoska","year":"2018","journal-title":"Bone"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/jbmr.2072","article-title":"Trends in fracture incidence: a population-based study over 20 years","volume":"29","author":"Amin","year":"2014","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0140-6736(98)09075-8","article-title":"Mortality after all major types of osteoporotic fracture in men and women: an observational study","volume":"353","author":"Nguyen","year":"1999","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD014707.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1210\/edrv-16-1-87","article-title":"Osteoporosis in men","volume":"16","author":"Orwoll","year":"1995","journal-title":"Endocrine Reviews"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s001980200100","article-title":"Survival and potential years of life lost after hip fracture in men and age-matched women","volume":"13","author":"Trombetti","year":"2002","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","article-title":"An estimate of the worldwide prevalence and disability associated with osteoporotic fractures","volume":"17","author":"Johnell","year":"2006","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1001\/archinte.162.19.2217","article-title":"Undertreatment of osteoporosis in men with hip fracture","volume":"162","author":"Kiebzak","year":"2002","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1210\/jc.2019-00192","article-title":"Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis","volume":"104","author":"Barrionuevo","year":"2019","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"18","key":"10.1002\/14651858.CD014707.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD014707.pub2-BIB0013|cit13","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004523.pub3","article-title":"Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal woman","author":"Wells","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD014707.pub2-BIB0014|cit14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003376.pub3","article-title":"Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women","author":"Wells","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/jgs.14668","article-title":"Osteoporosis treatment efficacy for men: a systematic review and meta-analysis","volume":"65","author":"Nayak","year":"2017","journal-title":"Journal of the American Geriatrics Society"},{"issue":"9","key":"10.1002\/14651858.CD014707.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1007\/s00198-015-3148-4","article-title":"Efficacy of bisphosphonates against osteoporosis in adult men: a meta-analysis of randomized controlled trials","volume":"26","author":"Chen","year":"2015","journal-title":"Osteoporosis International"},{"issue":"1","key":"10.1002\/14651858.CD014707.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40744-016-0030-6","article-title":"Comparative efficacy of bisphosphonates to prevent fracture in men with osteoporosis: a systematic review with network meta-analyses","volume":"3","author":"Zhou","year":"2016","journal-title":"Rheumatology and Therapy"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1155\/2019\/2594149","article-title":"Bisphosphonates for secondary prevention of osteoporotic fractures: a Bayesian network meta-analysis of randomized controlled trials","volume":"2019","author":"Shi","year":"2019","journal-title":"BioMed Research International"},{"issue":"11","key":"10.1002\/14651858.CD014707.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/jbmr.253","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research","volume":"25","author":"Shane","year":"2010","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/jama.2010.1098","article-title":"Exposure to oral bisphosphonates and risk of esophageal cancer","volume":"304","author":"Cardwell","year":"2010","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"c4444","DOI":"10.1136\/bmj.c4444","article-title":"Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort","volume":"341","author":"Green","year":"2010","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0022|cit22","first-page":"f114","article-title":"Exposure to bisphosphonates and risk of gastrointestinal cancers: series of nested case-control studies with QResearch and CPRD data","volume":"346","author":"Vinogradova","year":"2013","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0023|cit23","first-page":"1152","article-title":"Alendronate-associated esophageal injury: pathologic and endoscopic features","volume":"12","author":"Abraham","year":"1999","journal-title":"Modern Pathology"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0024|cit24","unstructured":"Update of safety review follow-up to the October 1, 2007 early communication about the ongoing safety review of bisphosphonates https:\/\/www.biospace.com\/article\/around-the-web\/update-of-safety-review-follow-up-to-the-october-1-2007-early-communication-about-the-ongoing-safety-review-of-bisphosphonates-\/"},{"issue":"9077","key":"10.1002\/14651858.CD014707.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(97)02342-8","article-title":"Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis","volume":"350","author":"Lindsay","year":"1997","journal-title":"Lancet"},{"issue":"19","key":"10.1002\/14651858.CD014707.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD014707.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s00198-019-04947-2","article-title":"Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis","volume":"30","author":"Reginster","year":"2019","journal-title":"Osteoporosis International"},{"issue":"1","key":"10.1002\/14651858.CD014707.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","article-title":"The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis","volume":"18","author":"Orwoll","year":"2003","journal-title":"Journal of Bone and Mineral Research"},{"issue":"5","key":"10.1002\/14651858.CD014707.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00198-004-1713-3","article-title":"Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy","volume":"16","author":"Orwoll","year":"2005","journal-title":"Osteoporosis International"},{"issue":"13","key":"10.1002\/14651858.CD014707.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"13","key":"10.1002\/14651858.CD014707.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","author":"Finkelstein","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD014707.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"5212","DOI":"10.1210\/jc.2003-030768","article-title":"Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis","volume":"88","author":"Hodsman","year":"2003","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1002\/jbmr.1800","article-title":"Safety of osteoanabolic therapy: a decade of experience","volume":"27","author":"Cipriani","year":"2012","journal-title":"Journal of Bone and Mineral Research"},{"issue":"9","key":"10.1002\/14651858.CD014707.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1007\/s00198-016-3607-6","article-title":"Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis","volume":"27","author":"Beaudoin","year":"2016","journal-title":"Osteoporosis International"},{"issue":"8","key":"10.1002\/14651858.CD014707.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD014707.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1210\/jc.2012-1569","article-title":"A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density","volume":"97","author":"Orwoll","year":"2012","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1210\/jc.2007-2814","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women","volume":"93","author":"Bone","year":"2008","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","article-title":"Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial","volume":"24","author":"Brown","year":"2009","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMe0905480","article-title":"Increasing options for the treatment of osteoporosis","volume":"361","author":"Khosla","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1359\/jbmr.070809","article-title":"Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD","volume":"22","author":"Lewiecki","year":"2007","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD014707.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/COC.0b013e31824be20e","article-title":"Efficacy and safety of denosumab versus zoledronic acid in patients with bone metastases: a systematic review and meta-analysis","volume":"36","author":"Sun","year":"2013","journal-title":"American Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD014707.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s40618-024-02469-1","article-title":"Romosozumab for the treatment of osteoporosis \u2013 a systematic review","volume":"48","author":"M\u00e4kinen","year":"2025","journal-title":"Journal of Endocrinological Investigation"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0045|cit45","unstructured":"Background information for Bone, Reproductive and Urologic Drugs Advisory Committee 16 January 2019 biologics license application for romosozumab https:\/\/www.fda.gov\/media\/121255\/download"},{"issue":"9","key":"10.1002\/14651858.CD014707.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1007\/s40520-023-02478-9","article-title":"Efficacy of osteoporosis pharmacological treatments in men: a systematic review and meta-analysis","volume":"35","author":"Beaudart","year":"2023","journal-title":"Aging Clinical and Experimental Research"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"241\u201351","DOI":"10.1038\/s41584-024-01094-9","article-title":"Evidence-Based Guideline for the management of osteoporosis in men","volume":"20","author":"Fuggle","year":"2024","journal-title":"Nature Reviews Rheumatology"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1097\/MJT.0000000000000446","article-title":"Alendronate for the treatment of osteoporosis in men: a meta-analysis of randomized controlled trials","volume":"24","author":"Xu","year":"2017","journal-title":"American Journal of Therapeutics"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1007\/s00198-009-0917-y","article-title":"Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status","volume":"20","author":"Langdahl","year":"2009","journal-title":"Osteoporosis International"},{"issue":"7","key":"10.1002\/14651858.CD014707.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1210\/jc.2013-4175","article-title":"Fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT)","volume":"99","author":"Nakamura","year":"2014","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"9","key":"10.1002\/14651858.CD014707.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1210\/jc.2017-02163","article-title":"A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis","volume":"103","author":"Lewiecki","year":"2018","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD014707.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/mab.2019.0049","article-title":"Safety of romosozumab in osteoporotic men and postmenopausal women: a meta-analysis and systematic review","volume":"39","author":"Mariscal","year":"2020","journal-title":"Monoclonal Antibodies in Immunodiagnosis and Immunotherapy"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0053|cit53","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis Revision 2 https:\/\/www.ema.europa.eu\/en\/evaluation-new-medicinal-products-treatment-primary-osteoporosis"},{"issue":"2","key":"10.1002\/14651858.CD014707.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3899\/jrheum.121306","article-title":"Updated method guidelines for Cochrane Musculoskeletal Group systematic reviews and metaanalyses","volume":"41","author":"Ghogomu","year":"2014","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0055|cit55","unstructured":"Higgins JP Lasserson T Thomas J Flemyng E Churchill R Methodological Expectations of Cochrane Intervention Reviews (MECIR) Cochrane: London. Version August 2023"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"International Journal of Surgery (London, England)"},{"issue":"8","key":"10.1002\/14651858.CD014707.pub2-BIB0057|cit57","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014707","article-title":"Pharmacological therapies for the prevention of fractures in men","author":"Braten","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0058|cit58","unstructured":"Lefebvre C, Glanville J, Briscoe S, Featherstone R, Littlewood A, Metzendorf M-I, et al. Technical Supplement to Chapter 4: Searching for and selecting studies (chapter last updated September 2024). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0060|cit60","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2026"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0061|cit61","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.2"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0062|cit62","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2026"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0063|cit63","unstructured":"Higgins JP Eldridge S Li T Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.2"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1056\/NEJMoa1204061","article-title":"Fracture risk and zoledronic acid therapy in men with osteoporosis","volume":"367","author":"Boonen","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0065|cit65","first-page":"112","article-title":"Antifracture efficacy and safety of once-yearly zoledronic acid 5 mg in men with osteoporosis: a prospective, randomized, controlled trial","volume":"22","author":"Boonen","year":"2011","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0066|cit66","first-page":"23","article-title":"Reduction in incidence of vertebral fractures with once yearly zoledronic acid in men with osteoporosis","volume":"26","author":"Boonen","year":"2011","journal-title":"Journal of Bone and Mineral Research"},{"issue":"9","key":"10.1002\/14651858.CD014707.pub2-BIB0067|cit67","first-page":"873","article-title":"Fracture risk and zoledronic acid in men with osteoporosis","volume":"368","author":"Boonen","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"21","key":"10.1002\/14651858.CD014707.pub2-BIB0068|cit68","first-page":"79","article-title":"Efficacy of once-yearly zoledronic acid 5 mg in men with osteoporosis with different levels of serum total testosterone","volume":"23","author":"Boonen","year":"2012","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0069|cit69","unstructured":"Deeks JJ Higgins JPT Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.2"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00296-005-0004-4","article-title":"Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study","volume":"26","author":"Ringe Faber","year":"2006","journal-title":"Rheumatology International"},{"issue":"3","key":"10.1002\/14651858.CD014707.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00296-008-0689-2","article-title":"Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study","volume":"29","author":"Ringe","year":"2009","journal-title":"Rheumatology International"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0072|cit72","unstructured":"Page MJ Higgins JP Sterne JAC Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.2"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/bmj.c365","article-title":"The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews","volume":"340","author":"Kirkham","year":"2010","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0074|cit74","first-page":"h2088","article-title":"Overdiagnosis of bone fragility in the quest to prevent hip fracture","volume":"350","author":"J\u00e4rvinen","year":"2015","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0075|cit75","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.2"},{"issue":"3","key":"10.1002\/14651858.CD014707.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jphys.2023.05.012","article-title":"Research Note: Interpreting findings of a systematic review using GRADE methods","volume":"69","author":"Brennan","year":"2023","journal-title":"Journal of Physiotherapy"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0077|cit77","unstructured":"Sch\u00fcnemann HJ, Higgins JP, Vist GE, Glasziou P, Akl EA, Skoetz N, et al. Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.2"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jclinepi.2022.07.014","article-title":"GRADE Guidance 34: update on rating imprecision using a minimally contextualized approach","volume":"150","author":"Zeng","year":"2022","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD014707.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1359\/jbmr.081214","article-title":"Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study","volume":"24","author":"Boonen","year":"2009","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.bone.2012.06.016","article-title":"Evidence for safety and efficacy of risedronate in men with osteoporosis over 4years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study","volume":"51(3)","author":"Boonen","year":"2012","journal-title":"Bone"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0081|cit81","unstructured":"Efficacy and safety of risedronate therapy administered 35 mg once a week in men with osteoporosis https:\/\/clinicaltrials.gov\/show\/NCT00619957"},{"issue":"11","key":"10.1002\/14651858.CD014707.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1111\/j.1532-5415.2011.03666.x","article-title":"Once-yearly zoledronic acid in older men compared with women with recent hip fracture","volume":"59","author":"Boonen","year":"2011","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00223-011-9543-8","article-title":"Subtrochanteric fractures in bisphosphonate-naive patients: results from the HORIZON-recurrent fracture trial","volume":"89(6)","author":"Adachi","year":"2011","journal-title":"Calcified Tissue International"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0084|cit84","first-page":"15","article-title":"Effect of once-yearly zoledronic acid in men after recent hip fracture: Results from horizon recurrent fracture trial","volume":"25","author":"Boonen","year":"2010","journal-title":"Journal of Bone and Mineral Research"},{"issue":"6","key":"10.1002\/14651858.CD014707.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1185\/030079904125003683","article-title":"The HORIZON Recurrent Fracture Trial: design of a clinical trial in the prevention of subsequent fractures after low trauma hip fracture repair","volume":"20","author":"Colon-Emeric","year":"2004","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1359\/jbmr.090209","article-title":"Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture","volume":"24(7)","author":"Eriksen","year":"2009","journal-title":"Journal of Bone and Mineral Research"},{"issue":"12","key":"10.1002\/14651858.CD014707.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1002\/jbmr.2283","article-title":"Subgroup variations in bone mineral density response to zoledronic acid after hip fracture","volume":"29","author":"Magaziner","year":"2014","journal-title":"Journal of Bone and Mineral Research"},{"issue":"9","key":"10.1002\/14651858.CD014707.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1007\/s00198-010-1514-9","article-title":"Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON-Recurrent Fracture Trial","volume":"22","author":"Adachi","year":"2011","journal-title":"Osteoporosis International"},{"issue":"18","key":"10.1002\/14651858.CD014707.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD014707.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1002\/jbmr.4719","article-title":"The efficacy and safety of abaloparatide-SC in men with osteoporosis: a randomized clinical trial","volume":"37","author":"Czerwinski","year":"2022","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/13685530701661051","article-title":"The effects of daily alendronate, daily calcitonin and alendronate every other day on bone mineral density in osteoporotic men","volume":"10(4)","author":"Guven","year":"2007","journal-title":"Aging Male"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00774-009-0136-9","article-title":"The effects of weekly alendronate therapy in Taiwanese males with osteoporosis","volume":"28(3)","author":"Hwang","year":"2010","journal-title":"Journal of Bone and Mineral Metabolism"},{"issue":"9","key":"10.1002\/14651858.CD014707.pub2-BIB0093|cit93","first-page":"3069","article-title":"Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers","volume":"85","author":"Kurland","year":"2000","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"9","key":"10.1002\/14651858.CD014707.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1210\/jc.2017-02163","article-title":"A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis","volume":"103","author":"Lewiecki","year":"2018","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0095|cit95","first-page":"409","article-title":"Results of a phase 3 clinical trial to evaluate the efficacy and safety of romosozumab in men with osteoporosis","volume":"68","author":"Lewiecki","year":"2016","journal-title":"Arthritis & Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD014707.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2165\/00044011-200424060-00003","article-title":"Weekly oral alendronic acid in male osteoporosis","volume":"24","author":"Miller","year":"2004","journal-title":"Clinical Drug Investigation"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1056\/NEJM200008313430902","article-title":"Alendronate for the treatment of osteoporosis in men","volume":"343","author":"Orwoll","year":"2000","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","article-title":"The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis","volume":"18(1)","author":"Orwoll","year":"2003","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"970\u201376","DOI":"10.1016\/j.bone.2009.12.034","article-title":"Efficacy and safety of monthly ibandronate in men with low bone density","volume":"46","author":"Orwoll","year":"2010","journal-title":"Bone"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0100|cit100","unstructured":"The effect of oral ibandronate in male osteoporosis https:\/\/clinicaltrials.gov\/show\/NCT00397839"},{"issue":"1","key":"10.1002\/14651858.CD014707.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00198-011-1732-9","article-title":"Effect of monthly ibandronate on hip structural geometry in men with low bone density","volume":"23","author":"Genant","year":"2012","journal-title":"Osteoporosis International"},{"issue":"10","key":"10.1002\/14651858.CD014707.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1002\/jbmr.119","article-title":"Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study","volume":"25","author":"Orwoll","year":"2010","journal-title":"Journal of Bone and Mineral Research"},{"issue":"9","key":"10.1002\/14651858.CD014707.pub2-BIB0103|cit103","first-page":"3161\u201369","article-title":"A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density","volume":"97","author":"Orwoll","year":"2012","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD014707.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1210\/jc.2014-4079","article-title":"A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial","volume":"100","author":"Langdahl","year":"2015","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0105|cit105","first-page":"12","article-title":"The effect of denosumab on bone mineral density (BMD) assessed by baseline bone turnover in men with low BMD","volume":"27","author":"Miller","year":"2012","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0106|cit106","first-page":"9","article-title":"Relationship between baseline bone turnover marker levels and bone mineral density changes in men with low bone mineral density receiving denosumab or placebo","volume":"64","author":"Orwoll","year":"2012","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0107|cit107","unstructured":"Study to compare the efficacy and safety of denosumab versus placebo in males with osteoporosis https:\/\/clinicaltrials.gov\/show\/NCT00980174"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0108|cit108","unstructured":"A multicenter, randomized, double-blind, placebo controlled study to compare the efficacy and safety of denosumab versus placebo in males with low bone mineral density https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2009-010205-37\/BE"},{"issue":"11","key":"10.1002\/14651858.CD014707.pub2-BIB0109|cit109","first-page":"5252\u201355","article-title":"Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study","volume":"86","author":"Ringe","year":"2001","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD014707.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s00296-003-0388-y","article-title":"Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study","volume":"24","author":"Ringe","year":"2004","journal-title":"Rheumatology International"},{"issue":"1","key":"10.1002\/14651858.CD014707.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s12020-012-9819-4","article-title":"Combination therapy with risedronate and teriparatide in male osteoporosis","volume":"44","author":"Walker","year":"2013","journal-title":"Endocrine"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0112|cit112","first-page":"12","article-title":"Treatment of male osteoporosis: risedronate, teriparatide or both","volume":"27","author":"Walker","year":"2012","journal-title":"Journal of Bone and Mineral Research"},{"issue":"22","key":"10.1002\/14651858.CD014707.pub2-BIB0113|cit113","first-page":"1868","article-title":"Effects of teriparatide compared with risedronate on recovery after pertrochanteric hip fracture: results of a randomized, active-controlled, double-blind clinical trial at 26 weeks","volume":"98","author":"Aspenberg","year":"2016","journal-title":"Journal of Bone & Joint Surgery - American Volume"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0114|cit114","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s00198-008-0767-z","article-title":"Effect of alendronate in elderly patients after low trauma hip fracture repair","volume":"20(6)","author":"Cecilia","year":"2009","journal-title":"Osteoporosis International"},{"issue":"1","key":"10.1002\/14651858.CD014707.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4314\/tjpr.v18i1.8","article-title":"Effect of co-administration of alendronate and allan sodium phosphate for the management of osteoporosis","volume":"18","author":"Chen","year":"2019","journal-title":"Tropical Journal of Pharmaceutical Research"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.2147\/CIA.S63987","article-title":"Additive effects of nutritional supplementation, together with bisphosphonates, on bone mineral density after hip fracture: a 12-month randomized controlled study","volume":"9","author":"Flodin","year":"2014","journal-title":"Clinical Interventions in Aging"},{"issue":"7","key":"10.1002\/14651858.CD014707.pub2-BIB0117|cit117","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.12669\/pjms.36.7.1964","article-title":"Clinical effect of Zoledronic Acid in the treatment of Senile Osteoporosis","volume":"36","author":"Kong","year":"2020","journal-title":"Pakistan Journal of Medical Sciences"},{"issue":"3","key":"10.1002\/14651858.CD014707.pub2-BIB0118|cit118","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/S8756-3282%2800%2900437-3","article-title":"Effects of clodronate on vertebral fracture risk in osteoporosis: A 1-year interim analysis","volume":"28","author":"McCloskey","year":"2001","journal-title":"Bone"},{"issue":"5","key":"10.1002\/14651858.CD014707.pub2-BIB0119|cit119","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/jbm4.10054","article-title":"Efficacy of switching from teriparatide to bisphosphonate or denosumab: a prospective, randomized, open-label trial","volume":"2","author":"Niimi","year":"2018","journal-title":"JBMR Plus"},{"issue":"10","key":"10.1002\/14651858.CD014707.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.4314\/tjpr.v20i10.26","article-title":"Comparative efficacy and safety of alendronate and teriparatide in bone loss reduction and prevention of vertebral fracture in osteoporotic Chinese patients","volume":"20","author":"Qi","year":"2021","journal-title":"Tropical Journal of Pharmaceutical Research"},{"issue":"5","key":"10.1002\/14651858.CD014707.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00296-006-0288-z","article-title":"Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial)","volume":"27","author":"Ringe","year":"2007","journal-title":"Rheumatology International"},{"issue":"4","key":"10.1002\/14651858.CD014707.pub2-BIB0122|cit122","first-page":"2371","article-title":"The curative effect of the additional administration of ibandronate sodium and calcitriol on elderly patients with osteoporosis","volume":"13","author":"Zhang","year":"2020","journal-title":"International Journal of Clinical and Experimental Medicine"},{"issue":"3","key":"10.1002\/14651858.CD014707.pub2-BIB0123|cit123","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/os.12701","article-title":"Fall prevention and anti-osteoporosis in osteopenia patients of 80 years of age and older: a randomized controlled study","volume":"12","author":"Zhou","year":"2020","journal-title":"Orthopaedic Audio-Synopsis Continuing Medical Education"},{"issue":"3","key":"10.1002\/14651858.CD014707.pub2-BIB0124|cit124","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s00198-020-05637-0","article-title":"Therapeutic efficacy of zoledronic acid combined with calcitriol in elderly patients receiving total hip arthroplasty or hemiarthroplasty for osteoporotic femoral neck fracture","volume":"32","author":"Zhu","year":"2021","journal-title":"Osteoporosis International"},{"issue":"13","key":"10.1002\/14651858.CD014707.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","author":"Finkelstein","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1210\/jc.2006-0190","article-title":"Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men","volume":"91(8)","author":"Finkelstein","year":"2006","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD014707.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00223-002-1085-7","article-title":"Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study","volume":"73","author":"Gonnelli","year":"2003","journal-title":"Calcified Tissue International"},{"issue":"1","key":"10.1002\/14651858.CD014707.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"183","DOI":"10.4314\/tjpr.v19i1.26","article-title":"Comparison of efficacy and safety of teriparatide and hyaluronic acid - Calcitonin combination treatments in Chinese osteoporotic patients with risk of bone fracture: a preliminary investigation","volume":"19","author":"Hou","year":"2020","journal-title":"Tropical Journal of Pharmaceutical Research"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0129|cit129","unstructured":"A one year multicenter, randomized, double-blind, placebo controlled, parallel group study to evaluate the efficacy and safety of a single intravenous 5 mg dose zoledronic acid for the treatment of osteoporosis in men - ND https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2006-005893-37"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0130|cit130","unstructured":"Clinical study of parathyroid hormone in preventing re-fracture after osteoporosis http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=ChiCTR1800016971"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0131|cit131","unstructured":"A study to compare the effect of teriparatide and zoledronic acid in osteoporosis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2017\/09\/009728"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0132|cit132","unstructured":"Randomized study of human parathyroid hormone in middle-aged men with idiopathic osteoporosis https:\/\/clinicaltrials.gov\/show\/NCT00004406"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0133|cit133","unstructured":"Efficacy and safety of zoledronic acid for the treatment of osteoporosis in men https:\/\/clinicaltrials.gov\/show\/NCT00097825"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0134|cit134","unstructured":"ONO-5920\/YM529 confirmatory study in involutional osteoporosis patients https:\/\/clinicaltrials.gov\/show\/NCT00794443"},{"issue":"6","key":"10.1002\/14651858.CD014707.pub2-BIB0135|cit135","first-page":"347","article-title":"Clinic effect of alendronate sodium treatment in osteoporosis patients with hip fracture","volume":"42","author":"Qiu","year":"2004","journal-title":"Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]"},{"issue":"6","key":"10.1002\/14651858.CD014707.pub2-BIB0136|cit136","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3969\/j.issn.1003-0034.2019.06.010","article-title":"Comparison of the clinical effects between Dihuang Decoction and alendronate sodium in the treatment of primary osteoporosis","volume":"32","author":"Wan","year":"2019","journal-title":"Zhongguo Gushang"},{"issue":"9","key":"10.1002\/14651858.CD014707.pub2-BIB0137|cit137","first-page":"1287","article-title":"Therapeutic effect of zoledronic acid on primary osteoporosis in elderly patients","volume":"32","author":"Xu","year":"2012","journal-title":"Nan Fang Yi Ke da Xue Xue Bao (Journal of Southern Medical University)"},{"issue":"2","key":"10.1002\/14651858.CD014707.pub2-BIB0138|cit138","first-page":"52","article-title":"Clinical trial of disodium etidronate in treatment of 180 cases of osteoporosis","volume":"3","author":"Yu","year":"1997","journal-title":"Chinese Journal of Osteoporosis"},{"issue":"3","key":"10.1002\/14651858.CD014707.pub2-BIB0139|cit139","first-page":"292","article-title":"Effect of Busheng Huoxue Capsule on the quality of life of primary osteoporosis senile males","volume":"34","author":"Zhang","year":"2014","journal-title":"Zhongguo Zhong Xi Yi Jie He za Zhi [Chinese Journal of Integrated Traditional and Western Medicine]"},{"issue":"1","key":"10.1002\/14651858.CD014707.pub2-BIB0140|cit140","first-page":"51","article-title":"Efficacy of bisphosphonates combined with recombinant human parathyroid hormone 1-34 in elderly patients with lumbar or Hip joint injury caused by osteoporosis","volume":"38","author":"Ziying S and Ping","year":"2019","journal-title":"Latin American Journal of Pharmacy"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0141|cit141","unstructured":"Preventing osteoporosis using denosumab https:\/\/clinicaltrials.gov\/show\/NCT02753283"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0142|cit142","unstructured":"Head to head comparison teriparatide products daily versus weekly for osteoporosis patients https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-UMIN000024503"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0143|cit143","unstructured":"Effect of subsequence treatment after romosozumab in patietns with osteoporosis: open-label, randomised contorlled trial http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN UMIN000040132"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0144|cit144","unstructured":"Verification of efficacy and safety of denosumab or ibandronate for patients with osteoporosis after treatment with romosozumab https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-jRCT1041190094"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0145|cit145","unstructured":"Comparative study of efficacy of minodronate, alendronate and risedronate in patients with osteoporosis http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN UMIN000011407"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0146|cit146","unstructured":"Verification of the impact on sequential therapy Of romosozumab according to the administration period of teriparatide http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN UMIN000036854"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0147|cit147","unstructured":"Examination of Efficacy and Safety of Other Anti-Resorption Drugs After 2-year-Denosumab Therapy in Japanese Osteoporosis Patients https:\/\/clinicaltrials.gov\/show\/NCT03755193"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0148|cit148","unstructured":"Zoledronate early to hip fracture patients - safe and effective? https:\/\/clinicaltrials.gov\/show\/NCT05025293"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0149|cit149","unstructured":"Phase II\/III clinical study of r484iv (ibandronic acid) for primary osteoporosis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-jRCT2080220364"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0150|cit150","unstructured":"The study of the early administration of alendronate on prevention of bone loss after hip fracture https:\/\/clinicaltrials.gov\/show\/NCT00346190"},{"issue":"5","key":"10.1002\/14651858.CD014707.pub2-BIB0151|cit151","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1111\/j.1532-5415.2006.00696.x","article-title":"Between-meal risedronate does not alter bone turnover in nursing home residents","volume":"54","author":"Agrawal","year":"2006","journal-title":"Journal of the American Geriatrics Society"},{"issue":"15","key":"10.1002\/14651858.CD014707.pub2-BIB0152|cit152","first-page":"S22\u20133","article-title":"Reduction in the risk of clinical fractures after a single dose of zoledronic acid 5mg","volume":"25","author":"Black","year":"2010","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0153|cit153","unstructured":"Role of zoledronic acid in osteoprotic patients https:\/\/ctri.nic.in\/Clinicaltrials\/login.php"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0154|cit154","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.bone.2015.07.036","article-title":"Administration of romosozumab improves vertebral trabecular and cortical bone as assessed with quantitative computed tomography and finite element analysis","volume":"81","author":"Graeff","year":"2015","journal-title":"Bone"},{"issue":"2","key":"10.1002\/14651858.CD014707.pub2-BIB0155|cit155","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/jcph.239","article-title":"Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study","volume":"54","author":"Padhi","year":"2014","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0156|cit156","first-page":"412","article-title":"Effectiveness of Intravenous ibandronate on bone mineral density in patient with osteoporosis treated with oral bisphosphonate low-responders-MOVEMENT study","volume":"33","author":"Hagino","year":"2018","journal-title":"Journal of Bone and Mineral Research"},{"issue":"6","key":"10.1002\/14651858.CD014707.pub2-BIB0157|cit157","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s00774-019-01005-z","article-title":"Effectiveness of monthly intravenous ibandronate on the low responders to oral bisphosphonate: the MOVEMENT study","volume":"37","author":"Hagino","year":"2019","journal-title":"Journal of Bone and Mineral Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD014707.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/PL00004182","article-title":"Effects of alendronate on bone density in men with primary and secondary osteoporosis","volume":"11","author":"Ho","year":"2000","journal-title":"Osteoporosis International"},{"issue":"SUPPL. 1","key":"10.1002\/14651858.CD014707.pub2-BIB0159|cit159","first-page":"S379","article-title":"Effect of monthly intravenous ibandronate injections on bone mineral density in Japanese osteoporosis patients","volume":"27","author":"Ikeda","year":"2016","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0160|cit160","unstructured":"Ikeda S The effect of once-weekly teriparatide administration on prevention of vertebral collapse in new thoracolumbar vertebral fractures-T-WRAP prospective randomized controlled study Journal of Bone and Mineral Research 2017"},{"issue":"8","key":"10.1002\/14651858.CD014707.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/BF03347354","article-title":"Intravenous ibandronate in men with osteoporosis: an open pilot study over 2 years","volume":"26","author":"Lamy","year":"2003","journal-title":"Journal of Endocrinological Investigation"},{"issue":"1","key":"10.1002\/14651858.CD014707.pub2-BIB0162|cit162","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/S0002-9270%2801%2904008-4","article-title":"The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: A placebo-controlled endoscopy study","volume":"97","author":"Lanza","year":"2002","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0163|cit163","unstructured":"Moon SH Park HM Shin CS Chung HY Chung YS Yoon BK Effects of monthly risedronate with cholecalciferol on 25-hydroxyvitamin d level and bone markers in Korean patients with osteoporosis Journal of Bone and Mineral Research 2011"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0164|cit164","unstructured":"BONDIR study: a study of intravenous bonviva (ibandronate) after recent vertebral osteoporotic fracture in patients with osteoporosis https:\/\/clinicaltrials.gov\/show\/NCT00493623"},{"issue":"2","key":"10.1002\/14651858.CD014707.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/ebm.6.2.55","article-title":"Alendronate increased bone mineral density and decreased vertebral fractures in men with osteoporosis","volume":"6","author":"Orwoll","year":"2001","journal-title":"Evidence-based Medicine"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0166|cit166","first-page":"149","article-title":"The impact of switching short-term teriparatide to denosumab comparing with treating denosumab alone in patients with osteoporotic hip fracture: 1-year follow-up","volume":"34","author":"Park","year":"2019","journal-title":"Journal of Bone and Mineral Research"},{"issue":"3","key":"10.1002\/14651858.CD014707.pub2-BIB0167|cit167","first-page":"56","article-title":"Patient acceptance and tolerability of risedronate for osteoporosis therapy - Results of a phase iv study. [German]","volume":"8","author":"Push","year":"2001","journal-title":"Journal fur Mineralstoffwechsel"},{"issue":"5","key":"10.1002\/14651858.CD014707.pub2-BIB0168|cit168","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s00296-006-0288-z","article-title":"Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial)","volume":"27","author":"Ringe","year":"2007","journal-title":"Rheumatology International"},{"issue":"SUPPL 2","key":"10.1002\/14651858.CD014707.pub2-BIB0169|cit169","first-page":"S397","article-title":"Combined alfacalcidol and alendronate therapy is superior to the respective monotherapies in established postmenopausal or male osteoporosis","volume":"30","author":"Ringe","year":"2019","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0170|cit170","doi-asserted-by":"publisher","first-page":"100217","DOI":"10.1016\/j.bonr.2019.100217","article-title":"The efficacy of osteoporotic treatment in patients with new spinal vertebral compression fracture pain, ADL, QOL, bone metabolism and fracture-healing - In comparison with weekly teriparatide with bisphosphonate","volume":"11","author":"Shigenobu","year":"2019","journal-title":"Bone Report"},{"issue":"1","key":"10.1002\/14651858.CD014707.pub2-BIB0171|cit171","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1186\/s12891-018-2309-y","article-title":"Open-label study of treatment with alendronate sodium plus vitamin D in men and women with osteoporosis in Thailand","volume":"19","author":"Songpatanasilp","year":"2018","journal-title":"BMC Musculoskeletal Disorders"},{"issue":"3","key":"10.1002\/14651858.CD014707.pub2-BIB0172|cit172","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00774-020-01180-4","article-title":"Long-term safety and effectiveness of denosumab in Japanese patients with osteoporosis: 3-year post-marketing surveillance study","volume":"39","author":"Tanaka","year":"2021","journal-title":"Journal of Bone and Mineral Metabolism"},{"issue":"8","key":"10.1002\/14651858.CD014707.pub2-BIB0173|cit173","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1007\/s00108-008-2180-2","article-title":"Zoledronic acid for preventing fractures","volume":"49","author":"Traut","year":"2008","journal-title":"Internist"},{"issue":"1","key":"10.1002\/14651858.CD014707.pub2-BIB0174|cit174","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s00774-014-0646-y","article-title":"The effect of teriparatide to alleviate pain and to prevent vertebral collapse after fresh osteoporotic vertebral fracture","volume":"34","author":"Tsuchie","year":"2016","journal-title":"Journal of Bone and Mineral Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD014707.pub2-BIB0175|cit175","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.bone.2008.05.002","article-title":"Alendronate\/vitamin D3 70 mg\/2800 IU with and without additional 2800 IU vitamin D3 for osteoporosis: Results from the 24-week extension of a 15-week randomized, controlled trial","volume":"44","author":"Binkley","year":"2009","journal-title":"Bone"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0176|cit176","unstructured":"Examination for the effect of combination therapy with alendronate and eldecalcitol in primary osteoporotic patients : a randomized active comparator study -Switch from alfacalcidol to eldecalcitol https:\/\/upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000008223"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0177|cit177","first-page":"318","article-title":"PF708, a therapeutic equivalent\/biosimilar teriparatide candidate, demonstrates comparable clinical profiles relative to forteo in osteoporosis patients","volume":"33","author":"Chen","year":"2018","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0178|cit178","unstructured":"Treatment with zoledronic acid subsequent to denosumab in osteoporosis https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2015-005529-37"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0179|cit179","unstructured":"Eldeacalcitol Phase IV study; combination therapy with alendronate https:\/\/www.clinicaltrials.jp\/user\/showCteDetailE.jsp?japicId=JapicCTI-111653"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0180|cit180","unstructured":"RGB-10 Phase 3 study -A comparative study to evaluate the similarity of RGB-10 to Forteo in patients with osteoporosis at high risk of fracture https:\/\/jrct.niph.go.jp\/en-latest-detail\/jRCT2080223153"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0181|cit181","unstructured":"Phase III clinical study of MN-10-T AI for patients with osteoporosis at higher fracture risk https:\/\/www.clinicaltrials.jp\/user\/showCteDetailE.jsp?japicId=JapicCTI-163477"},{"issue":"10","key":"10.1002\/14651858.CD014707.pub2-BIB0182|cit182","first-page":"959\u201366","article-title":"A phase I, randomized, double-blind, single-dose pharmacokinetic study to evaluate the biosimilarity of SB16 (proposed denosumab biosimilar) with reference denosumab in healthy male subjects","volume":"32","year":"2023","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0183|cit183","unstructured":"Efficacy of zoledronic acid in osteoporosis https:\/\/clinicaltrials.gov\/show\/NCT03183557"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0184|cit184","unstructured":"Park HM Effects of weekly risedronate with cholecalciferol on bone mineral density in Korean patients with osteoporosis Journal of Bone and Mineral Research 2015 30"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1002\/jbmr.4098","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial","volume":"35","author":"Solling","year":"2020","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0186|cit186","unstructured":"Treatment with zoledronic acid subsequent to denosumab in osteoporosis https:\/\/clinicaltrials.gov\/show\/NCT03087851"},{"issue":"10","key":"10.1002\/14651858.CD014707.pub2-BIB0187|cit187","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1002\/jbmr.4098","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial","volume":"35","author":"Solling","year":"2020","journal-title":"Journal of Bone and Mineral Research"},{"issue":"7","key":"10.1002\/14651858.CD014707.pub2-BIB0188|cit188","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/jbmr.4305","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a 2-year randomized study","volume":"36","author":"Solling","year":"2021","journal-title":"Journal of Bone and Mineral Research"},{"issue":"4","key":"10.1002\/14651858.CD014707.pub2-BIB0189|cit189","doi-asserted-by":"publisher","first-page":"474","DOI":"10.3349\/ymj.2009.50.4.474","article-title":"Comparison of the effects of alendronate and alfacalcidol on hip bone mineral density and bone turnover in Japanese men having osteoporosis or osteopenia with clinical risk factors for fractures","volume":"50","author":"Iwamoto","year":"2009","journal-title":"Yonsei Medical Journal"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00198-011-1583-4","article-title":"Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass","volume":"23","author":"Hadji","year":"2011","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00223-013-9734-6","article-title":"Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg\/month intravenous ibandronate versus 2.5 mg\/day oral risedronate in patients with primary osteoporosis","volume":"93","author":"Nakamura","year":"2013","journal-title":"Calcified Tissue International"},{"issue":"8","key":"10.1002\/14651858.CD014707.pub2-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1185\/03007995.2012.709838","article-title":"A multicenter randomized double-masked comparative study of different preparations of alendronate in osteoporosis \u2013 monthly (four weeks) intravenous versus once weekly oral administrations","volume":"28","author":"Shiraki","year":"2012","journal-title":"Current Medical Research and Opinion"},{"issue":"11","key":"10.1002\/14651858.CD014707.pub2-BIB0193|cit193","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s00198-004-1626-1","article-title":"Comparison of methods for the visual identification of prevalent vertebral fracture in osteoporosis","volume":"15","author":"Jiang","year":"2004","journal-title":"Osteoporosis International"},{"issue":"4","key":"10.1002\/14651858.CD014707.pub2-BIB0194|cit194","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/jbmr.3220","article-title":"Osteoporotic vertebral fracture prevalence varies widely between qualitative and quantitative radiological assessment methods: the Rotterdam study","volume":"33","author":"Oei","year":"2018","journal-title":"Journal of Bone and Mineral Research"},{"issue":"1","key":"10.1002\/14651858.CD014707.pub2-BIB0195|cit195","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00198-013-2460-0","article-title":"Mild morphometric vertebral fractures predict vertebral fractures but not non-vertebral fractures","volume":"25","author":"Johansson","year":"2014","journal-title":"Osteoporosis International"},{"issue":"7","key":"10.1002\/14651858.CD014707.pub2-BIB0196|cit196","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1007\/s00198-006-0106-1","article-title":"Influence of baseline deformity definition on subsequent vertebral fracture risk in postmenopausal women","volume":"17","author":"Melton","year":"2006","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.joms.2013.06.221","article-title":"Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate","volume":"72","author":"Ulmner","year":"2014","journal-title":"Journal of Oral and Maxillofacial Surgery"},{"issue":"1","key":"10.1002\/14651858.CD014707.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3109\/17453674.2015.1004149","article-title":"Risk of atypical femoral fracture during and after bisphosphonate use: full report of a nationwide study","volume":"86","author":"Schilcher","year":"2015","journal-title":"Acta Orthopaedica"},{"issue":"1","key":"10.1002\/14651858.CD014707.pub2-BIB0199|cit199","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/jbmr.2991","article-title":"Effects of abaloparatide-SC on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors","volume":"32","author":"Cosman","year":"2017","journal-title":"Journal of Bone and Mineral Research"},{"issue":"8381","key":"10.1002\/14651858.CD014707.pub2-BIB0200|cit200","doi-asserted-by":"publisher","first-page":"e068033","DOI":"10.1136\/bmj-2021-068033","article-title":"Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials","volume":"381","author":"Handel","year":"2023","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"7966","key":"10.1002\/14651858.CD014707.pub2-BIB0201|cit201","doi-asserted-by":"publisher","first-page":"g4120","DOI":"10.1136\/bmj.g4120","article-title":"Implications of expanding indications for drug treatment to prevent fracture in older men in United States: cross sectional and longitudinal analysis of prospective cohort study","volume":"349","author":"Ensrud","year":"2014","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"1","key":"10.1002\/14651858.CD014707.pub2-BIB0202|cit202","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/jbmr.4433","article-title":"Validation of the surrogate threshold effect for change in bone mineral density as a surrogate endpoint for fracture outcomes: the FNIH-ASBMR SABRE project","volume":"37","author":"Eastell","year":"2022","journal-title":"Journal of Bone and Mineral Research"},{"issue":"11","key":"10.1002\/14651858.CD014707.pub2-BIB0203|cit203","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S2213-8587(20)30338-7","article-title":"Bone mineral density as a surrogate biomarker for fracture risk reduction","volume":"8","author":"Shah","year":"2020","journal-title":"Lancet Diabetes & Endocrinology"},{"issue":"1","key":"10.1002\/14651858.CD014707.pub2-BIB0204|cit204","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.bone.2007.02.022","article-title":"DXA in vivo BMD methodology: an erroneous and misleading research and clinical gauge of bone mineral status, bone fragility, and bone remodelling","volume":"41","author":"Bolotin","year":"2007","journal-title":"Bone"},{"issue":"3","key":"10.1002\/14651858.CD014707.pub2-BIB0205|cit205","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/s00198-006-0106-1","article-title":"The fallacy of BMD: a critical review of the diagnostic use of dual X-ray absorptiometry","volume":"19","author":"Nielsen","year":"2000","journal-title":"Clinical Rheumatology"},{"issue":"10","key":"10.1002\/14651858.CD014707.pub2-BIB0206|cit206","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1302\/2046-3758.610.BJR-2016-0321.R1","article-title":"The effect of long-term bisphosphonate therapy on trabecular bone strength and microcrack density","volume":"6","author":"Jin","year":"2017","journal-title":"Bone & Joint Research"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0207|cit207","doi-asserted-by":"publisher","first-page":"115518","DOI":"10.1016\/j.bone.2020.115518","article-title":"Fifty years of bisphosphonates: What are their mechanical effects on bone?","volume":"138","author":"Burr","year":"2020","journal-title":"Bone"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0208|cit208","doi-asserted-by":"publisher","first-page":"43399","DOI":"10.1038\/srep43399","article-title":"Long-term effects of bisphosphonate therapy: perforations, microcracks and mechanical properties","volume":"7","author":"Ma","year":"2017","journal-title":"Scientific Reports"},{"issue":"2","key":"10.1002\/14651858.CD014707.pub2-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1359\/JBMR.0301228","article-title":"Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses","volume":"19","author":"Delmas","year":"2004","journal-title":"Journal of Bone and Mineral Research"},{"issue":"1","key":"10.1002\/14651858.CD014707.pub2-BIB0210|cit210","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1592\/phco.2006.26.1.104","article-title":"Examining the relationship between bone mineral density and fracture risk reduction during pharmacologic treatment of osteoporosis","volume":"26","author":"Divittorio","year":"2006","journal-title":"Pharmacotherapy. The Journal of Human Pharmacology and Drug Therapy"},{"issue":"27","key":"10.1002\/14651858.CD014707.pub2-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"875","DOI":"10.15585\/mmwr.mm6927a5","article-title":"Trends in nonfatal falls and fall-related injuries among adults aged \u2265 65 years \u2013 United States, 2012-2018","volume":"69","author":"Moreland","year":"2020","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"e4222","DOI":"10.1210\/clinem\/dgac486","article-title":"Abaloparatide Increases Lumbar Spine and Hip BMD in Japanese Patients With Osteoporosis: The Phase 3 ACTIVE-J Study","volume":"107","author":"Matsumoto","year":"2022","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"3","key":"10.1002\/14651858.CD014707.pub2-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s001980050214","article-title":"A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research Group","volume":"10","author":"Shiraki","year":"1999","journal-title":"Osteoporosis International"},{"issue":"10","key":"10.1002\/14651858.CD014707.pub2-BIB0214|cit214","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1056\/NEJMc1403799","article-title":"Risk of atypical femoral fracture during and after bisphosphonate use","volume":"371","author":"Schilcher","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD014707.pub2-BIB0215|cit215","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1471-2474-6-39","article-title":"Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women","volume":"6","author":"Sawka","year":"2005","journal-title":"BMC Musculoskeletal Disorders"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T05:36:01Z","timestamp":1792992961000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD014707.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":215,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd014707.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]}}}